

Anaesthesia recommendations for **Dyskeratosis congenita**

Disease name: Dyskeratosis congenita

ICD 10: Q82.8

Synonyms: Zinsser-Engman-Cole syndrome, Hoyeraal-Hreidarsson syndrome, Revesz syndrome, DC, DKC

Disease summary: Dyskeratosis congenita (DC) is a rare disease of abnormal telomere biology, leading to haematopoietic failure among other heterogeneous multisystem manifestations.

There are multiple forms of the condition, with varying patterns of inheritance. There is a 3:1 male:female predilection, and an incidence of approximately 1:1 000 000. The most common gene mutation (*DKC1*) in the X-linked form of DC results in impaired telomere maintenance. Other disease genes have been implicated, with both autosomal dominant and recessive inheritance, including: *TERC*, *TINF2*, *ACD*, *RTEL1*, *TERT*, *CTC1*, *NHP2*, *NOP10*, *PARN*, *WRAP53*, *NAF1*, *SNT1*, *POT1*, and *ZCCHC8*. (1-5) As all of these genes are important in telomere maintenance, DC is now regarded as principally a disorder of defective telomere maintenance.

DC classically presents with the clinical triad of dysplastic nails, lacy reticular pigmentation of the upper chest/neck, and oral leukoplakia (white plaques) (2). Bone marrow failure is common (80%). DC is also associated with pulmonary fibrosis, pulmonary arteriovenous malformations, poor dentition, oesophageal stenosis, cirrhosis, hepatopulmonary syndrome, vascular ectasias, urethral stenosis, peripheral neuropathy, immunodeficiency, and accelerated aging. Patients with DC have an elevated risk for leukemia as well as squamous cell cancers of the head and neck, skin, or anogenital regions (6). The treatment for DC is individualised according to symptoms. Haematopoietic stem cell transplant is considered in cases of bone marrow failure or leukemia (7.)

Medicine is in progress



Perhaps new knowledge

Every patient is unique

Perhaps the diagnosis is wrong



Find more information on the disease, its centres of reference and patient organisations on Orphanet: www.orpha.net

Typical surgery

Dental procedures, ophthalmologic procedures, bone marrow aspirate, liver biopsy, gastroscopy, colonoscopy, head and neck tumour resection. There are also case reports of organ transplants in this patient population (i.e., liver, lung)(8-10).

Type of anaesthesia

There are very few published case reports of anaesthetic management in DC (10-14). General anaesthesia has been described for patients with DC. Balanced anaesthetic maintenance with volatiles, opioids, and/or propofol is effective.

Given the high propensity for bone marrow failure in this patient population, thrombocytopenia and coagulopathy must be ruled out prior to providing neuraxial anaesthesia or performing regional anaesthesia techniques with high risk for bleeding. Furthermore, due to the telomere defect, wound healing and tissue repair are not completely normal. Careful surgical technique is important for DC patients undergoing any operative procedure, and they often require a longer recovery time compared to non-DC patients.

Necessary additional pre-operative testing (beside standard care)

Neurologic examination and documentation of pre-existing peripheral neuropathies is recommended. A careful airway examination is also essential.

Full blood count (including platelet count), coagulation profile, type and screen should be obtained, as should standard liver and renal function tests.

Patients with poor exercise tolerance, known pulmonary fibrosis, or pulmonary arteriovenous malformations may warrant pulmonary function testing, room air arterial blood gas, and/or an echocardiographic study.

A pre-operative haematology consult will guide peri-operative medication and blood product management.

Particular preparation for airway management

Patients with DC may be at risk for difficult intubation. The underlying telomere defect commonly results in poor dentition and friable oral tissue. Oropharyngeal tumours may distort the airway anatomy. Mandibular hypoplasia has also been reported in DC.

Pulmonary disease is a common (20%) complication of DC(15). With pulmonary fibrosis, poor lung compliance and gas exchange may further complicate airway management and ventilation, as may concomitant pulmonary hypertension, shunting, and right heart failure. Pulmonary arteriovenous malformations also lead to hypoxemia in patients with DC. Liver dysfunction resulting in ascites may further limit safe apnoea time.

A thorough airway examination is indicated. Adjuncts should be immediately available for safe tracheal intubation (e.g., supraglottic devices, video laryngoscope, flexible broncho-

scope). Apnoeic oxygen may be advisable for patients with pulmonary complications and apnoea intolerance. Efforts should be made to avoid traumatizing the oral mucosa, which may be prone to bleeding.

Particular preparation for transfusion or administration of blood products

Neutropenia, anaemia, thrombocytopenia, and pancytopenia are commonly seen in DC. Preoperative evaluation of full blood count is essential, with transfusion thresholds individualized since chronically anaemic patients may be adapted to lower haemoglobin levels. The immunomodulatory effects of blood product transfusion should be carefully considered in these immunocompromised patients.

Blood products should be leukodepleted, irradiated (if patient is lymphopenic), and CMV-negative. Avoid blood donations by relatives if stem cell transplant is being considered, as this may increase the risk of future graft rejection. Indeed, stem cell transplant candidates should have the minimal necessary exposure to red cells or platelets (2,16).

Blood conservation strategies are likely beneficial for this patient population. Consider administering tranexamic acid to avoid fibrinolysis (17). Use of topical haemostatic agents have not been described but may be useful.

Pre-operative administration of granulocyte colony-stimulating factor (GCSF) for treatment of leukopenia has been described (14). However, in patients taking androgen therapy for DC, concurrent GCSF administration has been implicated in life-threatening splenic rupture (18).

Particular preparation for anticoagulation

The need for perioperative anticoagulation must be weighed against bleeding risks and should be addressed in a multidisciplinary fashion.

Particular precautions for positioning, transportation and mobilisation

Not reported.

Interactions of chronic disease and anaesthesia medications

Not reported. Liver failure may be associated with prolonged elimination of anaesthetic medications, such as opioids, benzodiazepines, and neuromuscular blocking agents. In such instances, choosing medications that are eliminated independently of liver function may result in more predictable offset of medication effects.

Commonly used anaesthetic agents may be administered to patients with pulmonary complications of dyskeratosis congenita. Most halogenated volatile anaesthetics have bronchodilatory properties, although desflurane may cause bronchial irritation. At higher concentrations, volatile anaesthetics reverse hypoxic pulmonary vasoconstriction and may worsen intrapulmonary shunting. Nitrous oxide may increase pulmonary vascular resistance and worsen pulmonary hypertension; additionally, it may confer risk of air trapping and

pneumothorax in patients with pulmonary honeycomb cysts or bullae. Avoidance of excessive sedation and respiratory depression is advisable.

Anaesthetic procedure

General anaesthesia has been performed successfully in DC. There are no specific restrictions on the types of medications for induction or maintenance, though the presence of significant liver dysfunction may support the selection of agents that do not depend on hepatic clearance. Careful planning is necessary to ensure safe airway management. For patients with pulmonary fibrosis, a restrictive approach to fluid management is preferred and prolonged hyperoxygenation should be avoided, in order to avoid exacerbating alveolar dysfunction (19). Any decision to pursue elective surgery under general anaesthesia should be carefully weighed against the risk of pulmonary exacerbation.

No reported literature on regional anaesthesia in patients with DC. Given the risk of pulmonary complications, regional anaesthesia may often be preferable to general anaesthesia (19). Neuraxial anaesthesia may be unsafe in the context of severe thrombocytopenia. However, regional techniques with low risk of bleeding may be considered. Continuous regional anaesthesia catheters may be helpful for postoperative analgesia, but this must be weighed against the risk of infection in immunocompromised patients.

Dental procedures using local anaesthesia have been described (20).

Overall, there are very few reports describing anaesthetic management of patients with DC (10,13,14,20).

Particular or additional monitoring

Standard monitors should be used as appropriate (e.g., electrocardiogram, non-invasive blood pressure, pulse oximetry, capnography, gas analyser).

Intraoperative transoesophageal echocardiography may be indicated for patients with pulmonary hypertension and right heart failure, but oesophageal probe placement may be difficult or prone to complications if there are oesophageal strictures or varices. Invasive arterial blood pressure transduction and stroke volume variation may also guide fluid management.

Urethral stenosis may hinder insertion of urinary catheters.

Intraoperative use of thromboelastography has not been described but is likely helpful for managing acute haemorrhage.

Possible complications

Difficult airway management is a significant concern, as are postoperative pulmonary complications. Patients with poor pulmonary function may require post-operative ventilatory support.

Haemorrhage and opportunistic infection are complications relating to bone marrow failure.

Meticulous attention to aseptic technique and administration of surgical antibiotic prophylaxis are essential given immunocompromise.

Post-operative care

Patients with pulmonary dysfunction may require prolonged post-operative ventilatory support in the intensive care unit and may benefit from non-invasive positive pressure ventilation after extubation.

Continued dosing of tranexamic acid and antibiotic prophylaxis until 48 hours post-operatively has been reported (17).

Disease-related acute problems and effect on anaesthesia and recovery

Airway management and ventilation considerations as mentioned previously.

Ambulatory anaesthesia

Minor procedures can be considered as day cases, particularly in patients with limited systemic manifestations of DC. Local and regional anaesthetic techniques are preferred in patients with pulmonary compromise (19).

Obstetrical anaesthesia

No reported literature on obstetrical anaesthesia in patients with DC. Pregnancy may be associated with new pancytopenia or worsening of existing cytopenias (1).

There must be careful consideration of risks associated with neuraxial anaesthesia (bleeding disorder) versus general anaesthesia (difficult airway).

References

1. Savage SA, Alter BP. Dyskeratosis Congenita. *Hematol Oncol Clin North Am* 2009;23(2):215–31
2. Savage SA. Dyskeratosis Congenita. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean L, Stephens K, et al., editors. *GeneReviews* [Internet]. Seattle WA: GeneReviews; 2009. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK22301/>
3. Dokal I. Dyskeratosis congenita. *Hematology Am Soc Hematol Educ Program* 2011;2011(1):480–486
4. Niewisch MR, Savage SA. An update on the biology and management of dyskeratosis congenita and related telomere biology disorders. *Expert Rev Hematol* 2019;12(12):1037–1052
5. Gable DL, Gaysinskaya V, Atik CC, Talbot CC, Kang B, Stanley SE, et al. ZCCHC8, the nuclear exosome targeting component, is mutated in familial pulmonary fibrosis and is required for telomerase RNA maturation. *Genes Dev* 2019;33(19-20):1381–1396
6. Alter BP, Giri N, Savage SA, Rosenberg P. Cancer in dyskeratosis congenita. *Blood* 2009;25(113):6549–6557
7. Fernandez Garcia MS, Teruya-Feldstein J. The diagnosis and treatment of dyskeratosis congenita: a review. *J Blood Med* 2014;157–167
8. Giri N, Lee R, Faro A, Huddleston CB, White FV, Alter BP, et al. Lung transplantation for pulmonary fibrosis in dyskeratosis congenita: Case report and systematic literature review. *BMC Blood Disord* 2011;11(1):3
9. Mahansaria SS, Kumar S, Bharathy KGS, Kumar S, Pamecha V. Liver Transplantation After Bone Marrow Transplantation for End Stage Liver Disease with Severe Hepatopulmonary Syndrome in Dyskeratosis Congenita: A Literature First. *J Clin Exp Hepatol* 2015;5(4):344–347
10. Singh A, Tandon M, Pandey CK, Pandey VK. Dyskeratosis congenita induced cirrhosis for liver transplantation-perioperative management. *Indian J Anaesth* 2015;59(5):312–314
11. Matsumura T, Jinno S, Sakurai J, Oono Y, Takusagawa Y, Omura K, et al. General anesthesia for the child with dyskeratosis congenital in oral surgery. *Case Rep Dent* 2013;41(3):296–297
12. Wong M, Wong C, Macaulay B. Anesthetic management of a patient with dyskeratosis congenita undergoing head and neck tumour dissection. *J Anaesth Crit Care Case Rep* 2019;5(2):16–19
13. Mitre CI, Corda DM, Dunca F, Iancu C. Anesthesia in a patient with dyskeratosis congenita presenting for urgent subtotal gastrectomy. *J Clin Anesth* 2015;27(7):612–615
14. Çağlar Torun A. Anesthetic management in a case of dyskeratosis congenita. *Anadolu Kliniği Tıp Bilimleri Dergisi* 2017:1–3
15. Dokal I. Dyskeratosis congenita in all its forms. *Br J Haematol* 2000;110(4):768–779
16. Gajewski JL, Johnson VV, Sandler SG, Sayegh A, Klumpp TR. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. *Blood* 2008;112(8):3036–3047
17. Davidovich E, Eimerl D, Aker M, Shapira J, Peretz B. Dyskeratosis congenita: Dental management of a medically complex child. *Pediatr Dent* 2005;27(3):244–248
18. Giri N, Pitel PA, Green D, Alter BP. Splenic peliosis and rupture in patients with dyskeratosis congenita on androgens and granulocyte colony-stimulating factor. *Br J Haematol* 2007;138(6):815–817
19. Savage SA, Cook EF, editors. *Dyskeratosis Congenita and Telomere Biology Disorders: Diagnosis and Management Guidelines*. New York, NY: Dyskeratosis Congenita Outreach [Internet]. Dyskeratosis Congenita Outreach, Inc; 2015. Available from: <https://www.dcoutreach.org/guidelines>
20. Baran I, Nalcaci R, Kocak M. Dyskeratosis congenita: Clinical report and review of the literature. *Int J Dent Hygiene* 2010;8(1):68–74.

Date last modified: **December 2019**

This recommendation was prepared by:

Author(s)

Mike Wong, Department of Anesthesia, Pain Management & Perioperative Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
mike.wong@dal.ca

Chrison Wong, Department of Anesthesia, Pain Management & Perioperative Medicine, Dalhousie University, Halifax, Nova Scotia, Canada

Bruce Macaulay, Department of Anesthesia, Pain Management & Perioperative Medicine, Dalhousie University, Halifax, Nova Scotia, Canada

Disclosure(s) The authors have no financial or other competing interest to disclose. This recommendation was unfunded.

This recommendation was reviewed by:

Reviewer 1

Inderjeet Dokal, Paediatrician, Centre for Genomics and Child Health Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK
i.dokal@qmul.ac.uk

Reviewer 2

Sharon A. Savage, Paediatrician and Paediatric Haematologist, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA

Disclosures The reviewers have no financial or other competing interest to disclose.

Please note that in this recommendation, the reviews are both by non-anaesthesiologists.
